In a highly speculative sector like small-cap biotech, Wall Street may not walk softly, but it certainly carries an exceptionally big stick. And today the Street focused on two stocks with hepatitis-C candidates in development, lavishing praise on one and throwing scorn on the other. Let's jump in and take a closer look at the logic behind the upgrades and downgrades and see what price movements those calls wrought.
To make sense of the winner, let's start with today's loser, Idenix Pharmaceuticals
Idenix shareholders can thank Bristol-Myers Squibb
Given all that, it's no surprise that Wall Street's new darling, Achillion
Now, it's incredibly early, but if everything goes right, Achillion is developing all the parts of a treatment cocktail that could potentially compete with what Gilead
Just don't expect a buyout for Achillion anytime soon. Although Gilead appears to have succeeded in buying a blockbuster where Bristol failed, executives are generally risk-averse. As Achillion continues to advance its drugs without stumbles, a partnership with a deep-pocketed company looking to stake a claim in the space is the more likely outcome.
Many investors are attracted to Amarin and biotechs like it since they hold the allure of substantial short-term gains. But there's more than one approach to building long-term wealth and retiring well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.
David Williamson holds no position in any company mentioned. Check out his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Vertex Pharmaceuticals and Gilead Sciences. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days. The Motley Fool has a disclosure policy.